ZA200300456B - New pharmaceutical composition. - Google Patents

New pharmaceutical composition. Download PDF

Info

Publication number: ZA200300456B
Authority: ZA; South Africa
Prior art keywords: bile acid; acid sequestrant; composition according; composition; treatment
Prior art date: 2000-07-28

Application number

ZA200300456A

Other languages

English (en)

Inventor

Pierre Barbier

Hans Lengsfeld

Paul Hadvary

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-28

Filing date

2003-01-16

Publication date

2004-04-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8169384&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200300456(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-01-16 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2004-04-16 Publication of ZA200300456B publication Critical patent/ZA200300456B/en

Links

239000008194 pharmaceutical composition Substances 0.000 title claims description 20
239000000203 mixture Substances 0.000 claims description 84
229920000080 bile acid sequestrant Polymers 0.000 claims description 72
AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical group CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims description 49
229940086609 Lipase inhibitor Drugs 0.000 claims description 47
229960001243 orlistat Drugs 0.000 claims description 41
238000000034 method Methods 0.000 claims description 38
229920001268 Cholestyramine Polymers 0.000 claims description 30
229920002911 Colestipol Polymers 0.000 claims description 28
208000008589 Obesity Diseases 0.000 claims description 24
GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 claims description 24
229960002604 colestipol Drugs 0.000 claims description 24
235000020824 obesity Nutrition 0.000 claims description 24
230000002265 prevention Effects 0.000 claims description 22
239000003814 drug Substances 0.000 claims description 21
239000000126 substance Substances 0.000 claims description 21
229920000858 Cyclodextrin Polymers 0.000 claims description 20
229920002472 Starch Polymers 0.000 claims description 18
239000003613 bile acid Substances 0.000 claims description 18
239000008107 starch Substances 0.000 claims description 18
235000019698 starch Nutrition 0.000 claims description 18
229920002905 Colesevelam Polymers 0.000 claims description 15
229920002678 cellulose Polymers 0.000 claims description 15
239000000546 pharmaceutical excipient Substances 0.000 claims description 15
150000003839 salts Chemical class 0.000 claims description 15
239000001913 cellulose Substances 0.000 claims description 14
ZNSIZMQNQCNRBW-UHFFFAOYSA-N sevelamer Chemical compound NCC=C.ClCC1CO1 ZNSIZMQNQCNRBW-UHFFFAOYSA-N 0.000 claims description 14
VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 claims description 13
230000000694 effects Effects 0.000 claims description 13
238000004519 manufacturing process Methods 0.000 claims description 13
229960003693 sevelamer Drugs 0.000 claims description 13
230000002496 gastric effect Effects 0.000 claims description 12
229920005654 Sephadex Polymers 0.000 claims description 9
239000012507 Sephadex™ Substances 0.000 claims description 9
238000002360 preparation method Methods 0.000 claims description 9
DEMLYXMVPJAVFU-UHFFFAOYSA-N 2-(chloromethyl)oxirane;2-methyl-1h-imidazole Chemical compound ClCC1CO1.CC1=NC=CN1 DEMLYXMVPJAVFU-UHFFFAOYSA-N 0.000 claims description 8
229920000881 Modified starch Polymers 0.000 claims description 8
230000002550 fecal effect Effects 0.000 claims description 8
235000019426 modified starch Nutrition 0.000 claims description 8
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 7
229960001152 colesevelam Drugs 0.000 claims description 7
230000002209 hydrophobic effect Effects 0.000 claims description 7
239000003352 sequestering agent Substances 0.000 claims description 7
208000034347 Faecal incontinence Diseases 0.000 claims description 6
230000013872 defecation Effects 0.000 claims description 6
239000007884 disintegrant Substances 0.000 claims description 6
239000000945 filler Substances 0.000 claims description 6
229920000856 Amylose Polymers 0.000 claims description 5
239000011230 binding agent Substances 0.000 claims description 5
239000003086 colorant Substances 0.000 claims description 5
235000003599 food sweetener Nutrition 0.000 claims description 5
239000000314 lubricant Substances 0.000 claims description 5
239000004094 surface-active agent Substances 0.000 claims description 5
239000003765 sweetening agent Substances 0.000 claims description 5
239000002552 dosage form Substances 0.000 claims description 4
239000003623 enhancer Substances 0.000 claims description 4
230000008569 process Effects 0.000 claims description 3
238000002156 mixing Methods 0.000 claims description 2
GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 claims 4
150000001875 compounds Chemical class 0.000 description 40
-1 formiates Chemical class 0.000 description 25
239000008187 granular material Substances 0.000 description 24
229920000642 polymer Polymers 0.000 description 22
JVIPLYCGEZUBIO-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-dioxoisoindole-5-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1=CC=C(F)C=C1 JVIPLYCGEZUBIO-UHFFFAOYSA-N 0.000 description 13
229920001425 Diethylaminoethyl cellulose Polymers 0.000 description 13
229940032147 starch Drugs 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 10
235000010980 cellulose Nutrition 0.000 description 10
238000005469 granulation Methods 0.000 description 10
230000003179 granulation Effects 0.000 description 10
239000000243 solution Substances 0.000 description 10
239000000725 suspension Substances 0.000 description 10
150000001412 amines Chemical class 0.000 description 9
239000004615 ingredient Substances 0.000 description 9
239000008213 purified water Substances 0.000 description 9
VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 8
108010011485 Aspartame Proteins 0.000 description 8
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 8
239000000605 aspartame Substances 0.000 description 8
235000010357 aspartame Nutrition 0.000 description 8
229960003438 aspartame Drugs 0.000 description 8
229940096699 bile acid sequestrants Drugs 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
125000000217 alkyl group Chemical group 0.000 description 7
239000002775 capsule Substances 0.000 description 7
239000003085 diluting agent Substances 0.000 description 7
238000007908 dry granulation Methods 0.000 description 7
239000003925 fat Substances 0.000 description 7
235000019197 fats Nutrition 0.000 description 7
239000007903 gelatin capsule Substances 0.000 description 7
239000003921 oil Substances 0.000 description 7
235000019198 oils Nutrition 0.000 description 7
229940002552 xenical Drugs 0.000 description 7
102000004882 Lipase Human genes 0.000 description 6
108090001060 Lipase Proteins 0.000 description 6
239000004367 Lipase Substances 0.000 description 6
239000005913 Maltodextrin Substances 0.000 description 6
229920002774 Maltodextrin Polymers 0.000 description 6
235000019421 lipase Nutrition 0.000 description 6
229940035034 maltodextrin Drugs 0.000 description 6
235000012054 meals Nutrition 0.000 description 6
239000008188 pellet Substances 0.000 description 6
229920003109 sodium starch glycolate Polymers 0.000 description 6
239000008109 sodium starch glycolate Substances 0.000 description 6
229940079832 sodium starch glycolate Drugs 0.000 description 6
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
229960000674 colesevelam hydrochloride Drugs 0.000 description 5
229920001577 copolymer Polymers 0.000 description 5
229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
235000019333 sodium laurylsulphate Nutrition 0.000 description 5
241000287828 Gallus gallus Species 0.000 description 4
229940127470 Lipase Inhibitors Drugs 0.000 description 4
KNDHRUPPBXRELB-UHFFFAOYSA-M [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride Chemical compound [Cl-].C1=CC(CC)=CC=C1C(C)CCC1=CC=C([N+](C)(C)C)C=C1 KNDHRUPPBXRELB-UHFFFAOYSA-M 0.000 description 4
239000003833 bile salt Substances 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
229960001678 colestyramine Drugs 0.000 description 4
235000005911 diet Nutrition 0.000 description 4
229940079593 drug Drugs 0.000 description 4
210000001035 gastrointestinal tract Anatomy 0.000 description 4
GACQNVJDWUAPFY-UHFFFAOYSA-N n'-[2-[2-(2-aminoethylamino)ethylamino]ethyl]ethane-1,2-diamine;hydrochloride Chemical group Cl.NCCNCCNCCNCCN GACQNVJDWUAPFY-UHFFFAOYSA-N 0.000 description 4
125000001453 quaternary ammonium group Chemical group 0.000 description 4
239000000454 talc Substances 0.000 description 4
229910052623 talc Inorganic materials 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
229920002307 Dextran Polymers 0.000 description 3
SIKWOTFNWURSAY-UHFFFAOYSA-N Lipstatin Natural products CCCCCCC1C(CC(CC=CCC=CCCCCC)C(=O)OC(CC(C)C)NC=O)OC1=O SIKWOTFNWURSAY-UHFFFAOYSA-N 0.000 description 3
235000019759 Maize starch Nutrition 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
108050006759 Pancreatic lipases Proteins 0.000 description 3
102000019280 Pancreatic lipases Human genes 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 3
239000011648 beta-carotene Substances 0.000 description 3
TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 3
235000013734 beta-carotene Nutrition 0.000 description 3
229960002747 betacarotene Drugs 0.000 description 3
210000000941 bile Anatomy 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
229960000913 crospovidone Drugs 0.000 description 3
230000037213 diet Effects 0.000 description 3
235000013367 dietary fats Nutrition 0.000 description 3
230000029087 digestion Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000037406 food intake Effects 0.000 description 3
230000000260 hypercholesteremic effect Effects 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
210000000936 intestine Anatomy 0.000 description 3
OQMAKWGYQLJJIA-CUOOPAIESA-N lipstatin Chemical compound CCCCCC[C@H]1[C@H](C[C@H](C\C=C/C\C=C/CCCCC)OC(=O)[C@H](CC(C)C)NC=O)OC1=O OQMAKWGYQLJJIA-CUOOPAIESA-N 0.000 description 3
239000007788 liquid Substances 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
239000000178 monomer Substances 0.000 description 3
USGYNNGHZHARJS-UHFFFAOYSA-N n-prop-2-enyldecan-1-amine Chemical compound CCCCCCCCCCNCC=C USGYNNGHZHARJS-UHFFFAOYSA-N 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 3
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
150000008163 sugars Chemical class 0.000 description 3
150000003626 triacylglycerols Chemical class 0.000 description 3
RISCULYDRMPQKP-UHFFFAOYSA-M trimethyl-[6-(prop-2-enylamino)hexyl]azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CCCCCCNCC=C RISCULYDRMPQKP-UHFFFAOYSA-M 0.000 description 3
OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 3
NXOLVMFMAFCDSR-UHFFFAOYSA-M 2-(chloromethyl)oxirane;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;chloride Chemical compound [Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C NXOLVMFMAFCDSR-UHFFFAOYSA-M 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
QYOVMAREBTZLBT-KTKRTIGZSA-N CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO QYOVMAREBTZLBT-KTKRTIGZSA-N 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 2
102100031416 Gastric triacylglycerol lipase Human genes 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
208000035150 Hypercholesterolemia Diseases 0.000 description 2
208000031226 Hyperlipidaemia Diseases 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
KHNXRSIBRKBJDI-UHFFFAOYSA-N Sevelamer hydrochloride Chemical compound Cl.NCC=C.ClCC1CO1 KHNXRSIBRKBJDI-UHFFFAOYSA-N 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
230000009471 action Effects 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
230000008901 benefit Effects 0.000 description 2
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
229940093761 bile salts Drugs 0.000 description 2
125000002091 cationic group Chemical group 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
229940097479 colestid Drugs 0.000 description 2
229940097362 cyclodextrins Drugs 0.000 description 2
230000010235 enterohepatic circulation Effects 0.000 description 2
230000029142 excretion Effects 0.000 description 2
210000003608 fece Anatomy 0.000 description 2
235000013305 food Nutrition 0.000 description 2
238000009472 formulation Methods 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
108010091264 gastric triacylglycerol lipase Proteins 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
210000003405 ileum Anatomy 0.000 description 2
239000008101 lactose Substances 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
229920000344 molecularly imprinted polymer Polymers 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
229940116369 pancreatic lipase Drugs 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
229940069328 povidone Drugs 0.000 description 2
230000009103 reabsorption Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
229960003027 sevelamer hydrochloride Drugs 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
238000007711 solidification Methods 0.000 description 2
230000008023 solidification Effects 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
150000005846 sugar alcohols Chemical class 0.000 description 2
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical group C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 1
BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
XNXVOFLYSLWSPW-UHFFFAOYSA-N 2-decoxy-6-methyl-3,1-benzoxazin-4-one Chemical compound C1=C(C)C=C2C(=O)OC(OCCCCCCCCCC)=NC2=C1 XNXVOFLYSLWSPW-UHFFFAOYSA-N 0.000 description 1
LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
NLCNJAXHGPNGCJ-UHFFFAOYSA-N 6-methyl-2-tetradecoxy-3,1-benzoxazin-4-one Chemical compound C1=C(C)C=C2C(=O)OC(OCCCCCCCCCCCCCC)=NC2=C1 NLCNJAXHGPNGCJ-UHFFFAOYSA-N 0.000 description 1
235000003911 Arachis Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
102000013392 Carboxylesterase Human genes 0.000 description 1
108010051152 Carboxylesterase Proteins 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
206010014476 Elevated cholesterol Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
AHLBNYSZXLDEJQ-UHFFFAOYSA-N N-formyl-L-leucylester Natural products CCCCCCCCCCCC(OC(=O)C(CC(C)C)NC=O)CC1OC(=O)C1CCCCCC AHLBNYSZXLDEJQ-UHFFFAOYSA-N 0.000 description 1
206010033307 Overweight Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229920002518 Polyallylamine hydrochloride Polymers 0.000 description 1
229920002873 Polyethylenimine Polymers 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
229920004482 WACKER® Polymers 0.000 description 1
RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 1
230000009102 absorption Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009056 active transport Effects 0.000 description 1
238000011360 adjunctive therapy Methods 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
239000003957 anion exchange resin Substances 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
239000003529 anticholesteremic agent Substances 0.000 description 1
229940127226 anticholesterol agent Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
125000005264 aryl amine group Chemical group 0.000 description 1
125000000751 azo group Chemical group [*]N=N[*] 0.000 description 1
230000027455 binding Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
235000021152 breakfast Nutrition 0.000 description 1
150000001649 bromium compounds Chemical class 0.000 description 1
239000000872 buffer Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
235000014121 butter Nutrition 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
229920006317 cationic polymer Polymers 0.000 description 1
MVCQKIKWYUURMU-UHFFFAOYSA-N cetilistat Chemical compound C1=C(C)C=C2C(=O)OC(OCCCCCCCCCCCCCCCC)=NC2=C1 MVCQKIKWYUURMU-UHFFFAOYSA-N 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
229940107170 cholestyramine resin Drugs 0.000 description 1
238000013375 chromatographic separation Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
229960002577 colestipol hydrochloride Drugs 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
239000000412 dendrimer Substances 0.000 description 1
229920000736 dendritic polymer Polymers 0.000 description 1
239000003599 detergent Substances 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
235000013681 dietary sucrose Nutrition 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000004945 emulsification Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
239000000499 gel Substances 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000000871 hypocholesterolemic effect Effects 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000031891 intestinal absorption Effects 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
239000002960 lipid emulsion Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
150000002688 maleic acid derivatives Chemical class 0.000 description 1
239000000463 material Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
XLSZMDLNRCVEIJ-UHFFFAOYSA-N methylimidazole Natural products CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
239000002694 phosphate binding agent Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
229920000083 poly(allylamine) Polymers 0.000 description 1
229920000962 poly(amidoamine) Polymers 0.000 description 1
229920001308 poly(aminoacid) Polymers 0.000 description 1
229920002627 poly(phosphazenes) Polymers 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920000768 polyamine Polymers 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920000570 polyether Polymers 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
210000003240 portal vein Anatomy 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
238000003653 radioligand binding assay Methods 0.000 description 1
229940020428 renagel Drugs 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
150000003890 succinate salts Chemical class 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000001117 sulphuric acid Substances 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
150000003892 tartrate salts Chemical class 0.000 description 1
229960003080 taurine Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
125000004417 unsaturated alkyl group Chemical group 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
235000019195 vitamin supplement Nutrition 0.000 description 1
239000001993 wax Substances 0.000 description 1
229940111503 welchol Drugs 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/721—Dextrans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Obesity (AREA)
Diabetes (AREA)
Virology (AREA)
Hematology (AREA)
Tropical Medicine & Parasitology (AREA)
Child & Adolescent Psychology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Gastroenterology & Hepatology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)

ZA200300456A 2000-07-28 2003-01-16 New pharmaceutical composition. ZA200300456B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP00116393		2000-07-28

Publications (1)

Publication Number	Publication Date
ZA200300456B true ZA200300456B (en)	2004-04-16

Family

ID=8169384

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200300456A ZA200300456B (en)	2000-07-28	2003-01-16	New pharmaceutical composition.

Country Status (37)

Country	Link
US (5)	US6756364B2 (es)
EP (1)	EP1307264B1 (es)
JP (2)	JP4265911B2 (es)
KR (1)	KR100572785B1 (es)
CN (1)	CN100423715C (es)
AR (1)	AR033548A1 (es)
AT (1)	ATE279961T1 (es)
AU (2)	AU8969901A (es)
BR (1)	BR0112799B1 (es)
CA (1)	CA2416901C (es)
CZ (1)	CZ302087B6 (es)
DE (1)	DE60106623T2 (es)
EC (1)	ECSP034450A (es)
EG (1)	EG24357A (es)
ES (1)	ES2230362T3 (es)
GT (1)	GT200100152A (es)
HR (1)	HRP20030029B1 (es)
HU (1)	HU229292B1 (es)
IL (2)	IL154008A0 (es)
JO (1)	JO2320B1 (es)
MA (1)	MA26937A1 (es)
ME (1)	ME00671B (es)
MX (1)	MXPA03000771A (es)
MY (1)	MY127247A (es)
NO (1)	NO330546B1 (es)
NZ (1)	NZ523684A (es)
PA (1)	PA8523201A1 (es)
PE (1)	PE20020336A1 (es)
PL (1)	PL204443B1 (es)
PT (1)	PT1307264E (es)
RS (1)	RS50397B (es)
RU (1)	RU2241462C2 (es)
SI (1)	SI1307264T1 (es)
TW (1)	TWI275395B (es)
UY (1)	UY26860A1 (es)
WO (1)	WO2002009815A2 (es)
ZA (1)	ZA200300456B (es)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI1307264T1 (en) *	2000-07-28	2005-02-28	F. Hoffmann-La Roche Ag	New pharmaceutical composition
CA2416900C (en) *	2000-07-28	2007-07-03	F. Hoffmann-La Roche Ag	The use of a combination of a lipase inhibitor and a pharmaceutically acceptable bile acid sequestrant for the prevention and treatment of diseases associated with high plasma cholesterol levels
US7033373B2 (en)	2000-11-03	2006-04-25	Satiety, Inc.	Method and device for use in minimally invasive placement of space-occupying intragastric devices
US7083629B2 (en)	2001-05-30	2006-08-01	Satiety, Inc.	Overtube apparatus for insertion into a body
US6558400B2 (en)	2001-05-30	2003-05-06	Satiety, Inc.	Obesity treatment tools and methods
CA2483002C (en) *	2002-04-26	2011-02-01	F. Hoffmann-La Roche Ag	New pharmaceutical composition
US6746460B2 (en)	2002-08-07	2004-06-08	Satiety, Inc.	Intra-gastric fastening devices
US7033384B2 (en)	2002-08-30	2006-04-25	Satiety, Inc.	Stented anchoring of gastric space-occupying devices
US7214233B2 (en)	2002-08-30	2007-05-08	Satiety, Inc.	Methods and devices for maintaining a space occupying device in a relatively fixed location within a stomach
DK1545562T3 (da) *	2002-09-09	2006-08-21	Tno	Forgrenede alfa-glucaner til vægtregulering
US7229428B2 (en)	2002-10-23	2007-06-12	Satiety, Inc.	Method and device for use in endoscopic organ procedures
US7220237B2 (en)	2002-10-23	2007-05-22	Satiety, Inc.	Method and device for use in endoscopic organ procedures
US6656194B1 (en)	2002-11-05	2003-12-02	Satiety, Inc.	Magnetic anchoring devices
ES2528631T3 (es)	2003-04-08	2015-02-11	Progenics Pharmaceuticals, Inc.	Formulaciones farmacéuticas que contienen metilnaltrexona
US7175638B2 (en)	2003-04-16	2007-02-13	Satiety, Inc.	Method and devices for modifying the function of a body organ
US7914543B2 (en)	2003-10-14	2011-03-29	Satiety, Inc.	Single fold device for tissue fixation
US7097650B2 (en)	2003-10-14	2006-08-29	Satiety, Inc.	System for tissue approximation and fixation
US8608946B2 (en) *	2003-12-19	2013-12-17	Shell Oil Company	Systems, methods, and catalysts for producing a crude product
US20050177176A1 (en)	2004-02-05	2005-08-11	Craig Gerbi	Single-fold system for tissue approximation and fixation
EP1713402B1 (en)	2004-02-13	2018-07-04	Ethicon Endo-Surgery, Inc.	Device for reducing stomach volume
WO2006004574A2 (en) *	2004-02-19	2006-01-12	Abbott Laboratories	Method for using gamma cyclodextrin to control blood glucose and insulin secretion
EP1725194B1 (en)	2004-02-27	2018-01-17	Ethicon Endo-Surgery, Inc.	Methods and devices for reducing stomach volume
US8628547B2 (en)	2004-03-09	2014-01-14	Ethicon Endo-Surgery, Inc.	Devices and methods for placement of partitions within a hollow body organ
US8449560B2 (en)	2004-03-09	2013-05-28	Satiety, Inc.	Devices and methods for placement of partitions within a hollow body organ
US9028511B2 (en)	2004-03-09	2015-05-12	Ethicon Endo-Surgery, Inc.	Devices and methods for placement of partitions within a hollow body organ
US8252009B2 (en)	2004-03-09	2012-08-28	Ethicon Endo-Surgery, Inc.	Devices and methods for placement of partitions within a hollow body organ
EP1750627B1 (en)	2004-03-26	2018-10-10	Ethicon Endo-Surgery, Inc.	System for reducing stomach volume
US20050276781A1 (en) *	2004-06-09	2005-12-15	Ross Edward A	Molecularly imprinted phosphate binders for therapeutic use
WO2006035296A1 (en) *	2004-09-27	2006-04-06	Ranbaxy Laboratories Limited	Process for the preparation of an orlistat derivative useful as reference standard in the determination of the purity of orlistat and process for the preparation of orlistat
US20060106288A1 (en)	2004-11-17	2006-05-18	Roth Alex T	Remote tissue retraction device
US9662325B2 (en)	2005-03-07	2017-05-30	The University Of Chicago	Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en)	2005-03-07	2013-08-27	The University Of Chicago	Use of opioid antagonists
EP1861096B1 (en) *	2005-03-07	2018-12-26	The University of Chicago	Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en)	2005-03-07	2013-09-03	The University Of Chicago	Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es)	2005-05-25	2007-11-14	Progenics Pharm Inc	SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es)	2005-05-25	2007-11-28	Progenics Pharm Inc	Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
RU2283114C1 (ru) *	2005-06-07	2006-09-10	Открытое акционерное общество "Нижегородский химико-фармацевтический завод"	Композиция, обладающая гепатопротекторной активностью и нормализующая обменные процессы
EP1897558B1 (en) *	2005-06-09	2013-09-04	Norgine BV	Solid preparation of 2-hexadecyloxy-6-methyl-4h-3,1-benzoxazin-4-one
CA2610922A1 (en) *	2005-06-13	2006-12-21	Yeda Research And Development Co. Ltd.	Use of allylmercaptocaptopril for treating or preventing obesity and obesity related diseases
AR056499A1 (es) *	2005-09-06	2007-10-10	Serapis Farmaceuticals Ltd	Compuestos
CA2626734A1 (en) *	2005-11-08	2007-05-18	Genzyme Corporation	Magnesium-containing polymers for the treatment of hyperphosphatemia
AU2006325820B2 (en)	2005-12-12	2013-02-14	Allaccem, Inc.	Methods and systems for preparing antimicrobial films and coatings
EP1803714A1 (en) *	2005-12-27	2007-07-04	KRKA, tovarna zdravil, d.d., Novo mesto	Process for preparing crystalline forms of orlistat
WO2007086054A2 (en) *	2006-01-25	2007-08-02	Yeda Research And Development Co. Ltd.	A process for preparing allylmercaptocaptopril (cpssa) and related asymmetrical disulfides
CN101404982A (zh) *	2006-02-14	2009-04-08	特瓦制药工业有限公司	脂族胺聚合物的药物制剂和它们的制造方法
ES2320265T3 (es) *	2006-02-14	2009-05-20	Teva Pharmaceutical Industries, Ltd.	Formulaciones farmaceuticas de polimeros amino alifaticos y procedimientos para su preparacion.
TWI489984B (zh)	2006-08-04	2015-07-01	Wyeth Corp	用於非經腸道傳輸化合物之配方及其用途
US7964182B2 (en) *	2006-09-01	2011-06-21	USV, Ltd	Pharmaceutical compositions comprising phosphate-binding polymer
EP2064252A2 (en)	2006-09-01	2009-06-03	Usv Limited	Process for the preparation of sevelamer hydrochloride and formulation thereof
US7662373B2 (en) *	2006-09-18	2010-02-16	Thompson Ronald J	Method and composition of a medicament to decrease the adverse events of Olistat, an oral lipase inhibitor
US20080069906A1 (en) *	2006-09-18	2008-03-20	Thompson Ronald J	Method and composition of a carminative herb or natural supplement to decrease the adverse effects of orlistat, and oral lipase inhibitor
GB0618725D0 (en) *	2006-09-23	2006-11-01	Jagotec Ag	Composition containing inhibitors of gastro-intestinal lipase
WO2008070308A2 (en) *	2006-10-24	2008-06-12	Thompson Md Ronald J	Method and composition of a carminative herb or natural supplement to decrease the adverse effects of orlistat, an oral lipase inhibitor, and a method with formulations to concurrently reduce fracture risk and insure appropriate fatsoluble vitamin supplementation when using orlistat, an oral lipase inhibitor, and a method o
PL2124884T3 (pl) *	2006-12-22	2020-01-31	Ironwood Pharmaceuticals, Inc.	Metody i kompozycje do leczenia zaburzeń przełyku
EP1944025A1 (en) *	2007-01-09	2008-07-16	Ranbaxy Laboratories Limited	Stable pharmaceutical compositions of orlistat
DK2125026T3 (en)	2007-02-21	2014-12-08	Allaccem Inc	FORMATIONS BASED ON bridged POLYCYCLIC COMPOUNDS FOR INHIBITION AND RELIEF OF DISEASES
DK2139890T3 (da)	2007-03-29	2014-08-25	Wyeth Llc	Perifere opioidreceptor-antagonister og anvendelser deraf
ES2570374T3 (es)	2007-03-29	2016-05-18	Progenics Pharm Inc	Antagonistas del receptor opioide periférico y usos de los mismos
CN101801979A (zh)	2007-03-29	2010-08-11	普罗热尼奇制药公司	(r)-n-溴化甲基纳曲酮的晶体形式及其用途
US20090023682A1 (en) *	2007-07-19	2009-01-22	Joseph Artiss	Composition Comprising Dietary Fat Complexer and Methods of Using Same
US8188068B2 (en) *	2007-08-10	2012-05-29	Allaccem, Inc.	Bridged polycyclic compound based compositions for coating oral surfaces in pets
US8153617B2 (en) *	2007-08-10	2012-04-10	Allaccem, Inc.	Bridged polycyclic compound based compositions for coating oral surfaces in humans
US8153618B2 (en) *	2007-08-10	2012-04-10	Allaccem, Inc.	Bridged polycyclic compound based compositions for topical applications for pets
US20090074833A1 (en) *	2007-08-17	2009-03-19	Whiteford Jeffery A	Bridged polycyclic compound based compositions for controlling bone resorption
EP2219614A1 (en) *	2007-10-15	2010-08-25	Inventis DDS Pvt Limited	Pharmaceutical composition of orlistat
EP2240489A1 (en)	2008-02-06	2010-10-20	Progenics Pharmaceuticals, Inc.	Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
PL216542B1 (pl)	2008-03-20	2014-04-30	Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna	Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
JP5647098B2 (ja)	2008-03-21	2014-12-24	ザユニヴァーシティーオヴシカゴ	オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療
US20100004218A1 (en) *	2008-06-20	2010-01-07	Whiteford Jeffery A	Bridged polycyclic compound based compositions for renal therapy
US20100016270A1 (en) *	2008-06-20	2010-01-21	Whiteford Jeffery A	Bridged polycyclic compound based compositions for controlling cholesterol levels
BRPI0918499A2 (pt) *	2008-09-02	2015-12-01	Usv Ltd	polímeros reticulados
CA2676881C (en)	2008-09-30	2017-04-25	Wyeth	Peripheral opioid receptor antagonists and uses thereof
CN102316872B (zh) *	2008-11-26	2016-12-21	萨蒂奥根制药公司	治疗肥胖症和糖尿病的胆汁酸再循环抑制剂
GB0900350D0 (en) *	2009-01-09	2009-02-11	Cambridge Entpr Ltd	Formulations of viable bacteria for oral delivery
WO2010093243A1 (en)	2009-02-12	2010-08-19	Coöperatieve Mirzorg U.A., Arnhem	Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
US20100330175A1 (en) *	2009-06-24	2010-12-30	Jobdevairakkam Christopher N	Cross-linked polyallylamine tablet core
WO2011075539A2 (en) *	2009-12-18	2011-06-23	Satiogen Pharmaceuticals, Inc.	Treatment of obesity or diabetes with bile acid sequestrants
WO2011150286A2 (en)	2010-05-26	2011-12-01	Satiogen Pharmaceuticals,Inc.	Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
WO2012064266A1 (en)	2010-11-04	2012-05-18	Albireo Ab	Ibat inhibitors for the treatment of liver diseases
US11154559B2 (en)	2011-09-29	2021-10-26	Ethicon Endo-Surgery, Inc.	Methods and compositions of bile acids
MX354242B (es)	2011-10-28	2018-02-20	Lumena Pharmaceuticals Inc	Nhibidores de la recirculación de ácidos biliares para el tratamiento de enfermedades hepáticas colestásicas pediátricas.
CN107375291A (zh)	2011-10-28	2017-11-24	鲁美纳医药公司	用于治疗高胆血症和胆汁淤积性肝病的胆汁酸再循环抑制剂
EP2591768B1 (en) *	2011-11-14	2014-07-16	Deva Holding Anonim Sirketi	Single unit dosage formulations of sevelamer and fat soluble vitamins and surface active agents
JP2013147488A (ja) *	2011-12-21	2013-08-01	Taisho Pharmaceutical Co Ltd	固形製剤
GB201122213D0 (en) *	2011-12-23	2012-02-01	Norgine Bv	Compositions
US8252312B1 (en) *	2011-12-27	2012-08-28	David Wong	Oral solid composition comprising a lipid absorption inhibitor
HRP20211036T1 (hr)	2012-11-06	2021-10-01	Sigrid Therapeutics Ab	Porozni materijal silicij-dioksida za upotrebu kao farmaceutski ili dijetetski aktivni sastojak
NZ709368A (en)	2012-12-21	2020-01-31	National Health Res Inst	Mesoporous silica nanoparticles for oil absorption
RU2552926C1 (ru) *	2014-06-23	2015-06-10	Общество с ограниченной ответственностью "ПРОМОМЕД"	Фармацевтическая комбинация для лечения и/или предупреждения нарушений, связанных с избыточным весом и/или ожирением, и способ лечения на ее основе
CN106659726A (zh)	2014-06-25	2017-05-10	Ea制药株式会社	固体制剂及其着色防止或着色减少方法
US10743813B2 (en)	2014-09-11	2020-08-18	Rattan Nath	Diabetes control using postprandial feedback
EP3012252A1 (en)	2014-10-24	2016-04-27	Ferring BV	Crystal modifications of elobixibat
ES2784446T3 (es) *	2016-02-09	2020-09-25	Albireo Ab	Microgránulos de colestiramina y métodos para la preparación de los mismos
US10786529B2 (en)	2016-02-09	2020-09-29	Albireo Ab	Oral cholestyramine formulation and use thereof
US10441604B2 (en)	2016-02-09	2019-10-15	Albireo Ab	Cholestyramine pellets and methods for preparation thereof
US10441605B2 (en)	2016-02-09	2019-10-15	Albireo Ab	Oral cholestyramine formulation and use thereof
JP2020530448A (ja) *	2017-08-09	2020-10-22	アルビレオ・アクチボラグ	コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
US11389545B2 (en) *	2018-01-09	2022-07-19	Aqua Regenerative Therapies Llc	Bioactive nanoparticles and methods for making same
US10793534B2 (en)	2018-06-05	2020-10-06	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
HUE070725T2 (hu)	2018-06-20	2025-06-28	Albireo Ab	Odevixibat kristálymódosulatai
US11007142B2 (en)	2018-08-09	2021-05-18	Albireo Ab	Oral cholestyramine formulation and use thereof
US10722457B2 (en)	2018-08-09	2020-07-28	Albireo Ab	Oral cholestyramine formulation and use thereof
US11549878B2 (en)	2018-08-09	2023-01-10	Albireo Ab	In vitro method for determining the adsorbing capacity of an insoluble adsorbant
CN108685848B (zh) *	2018-08-13	2020-09-01	中山万汉制药有限公司	一种奥利司他口服乳剂及其制备方法
NL2022615B1 (en)	2019-02-21	2020-08-31	Patrick Alexander Unger	Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight
CN111297826B (zh) *	2020-04-20	2021-08-03	鲁南制药集团股份有限公司	一种稳定的奥利司他胶囊及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3692895A (en) *	1970-09-08	1972-09-19	Norman A Nelson	Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
IT1052819B (it) *	1975-12-12	1981-07-20	Fargal Pharmasint Lab Biochim	Preparato inibitore dell assorbimento dei lipidi a base di dietilamminoetildestrano
CA1247547A (en)	1983-06-22	1988-12-28	Paul Hadvary	Leucine derivatives
DE3414609C1 (de) *	1984-04-18	1985-06-20	Daimler-Benz Ag, 7000 Stuttgart	Vorrichtung zur Beeinflussung eines Kuehlluftstromes
US4632925A (en) *	1985-10-07	1986-12-30	Hoffmann-La Roche Inc.	N-substituted diphenylpiperidines and antiobesity use thereof
IT1190349B (it) *	1986-06-16	1988-02-16	Prodotti Formenti Srl	Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
SU1697823A1 (ru) *	1988-08-01	1991-12-15	Киевский государственный институт усовершенствования врачей	Способ лечени алиментарно-конституционального ожирени
US5063210A (en) *	1989-04-20	1991-11-05	Lange Iii Louis G	Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption
US5344453A (en) *	1991-05-30	1994-09-06	Boston Medical Products, Inc.	Thyroplasty implant
US5616570A (en) *	1991-10-18	1997-04-01	Lange, Iii; Louis G.	Use of non-absorbable synthetic sulfated polysaccharides to decrease cholesterol absorbtion
CA2098167C (en) *	1992-06-24	2006-12-19	Dorothea Isler	Foodstuffs and feedstuffs containing a lipase inhibitor
US5607669A (en) *	1994-06-10	1997-03-04	Geltex Pharmaceuticals, Inc.	Amine polymer sequestrant and method of cholesterol depletion
TW381025B (en) *	1993-08-05	2000-02-01	Hoffmann La Roche	Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
US5667775A (en) *	1993-08-11	1997-09-16	Geltex Pharmaceuticals, Inc.	Phosphate-binding polymers for oral administration
US5569452A (en) *	1993-08-31	1996-10-29	Tsrl, Inc.	Pharmaceutical formulation having enhanced bile acid binding affinity
TW474813B (en) *	1994-06-10	2002-02-01	Geltex Pharma Inc	Alkylated composition for removing bile salts from a patient
US5545414A (en) *	1995-03-22	1996-08-13	Abbott Laboratories	Cholesterol lowering food product
JP3832871B2 (ja) *	1995-04-03	2006-10-11	日本製粉株式会社	リパーゼ阻害剤
KR19980702533A (ko)	1995-12-26	1998-07-15	도리이 신이찌로	프로시아니딘을 유효성분으로 하는 항비만제
US5612026A (en) *	1996-01-25	1997-03-18	The Procter & Gamble Company	Cholesterol lowering drink mix compositons
US5883109A (en)	1996-07-24	1999-03-16	Bristol-Myers Squibb Company	Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en)	1997-01-17	2000-05-23	Bristol-Myers Squibb Co.	Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US6004996A (en)	1997-02-05	1999-12-21	Hoffman-La Roche Inc.	Tetrahydrolipstatin containing compositions
JP3807464B2 (ja)	1997-11-17	2006-08-09	康二嘉島	肥満防止剤
GB9727131D0 (en)	1997-12-24	1998-02-25	Knoll Ag	Therapeutic agents
US6267952B1 (en)	1998-01-09	2001-07-31	Geltex Pharmaceuticals, Inc.	Lipase inhibiting polymers
CA2318417A1 (en)	1998-01-09	1999-07-15	Geltex Pharmaceuticals, Inc.	Fat-binding polymers
FI113356B (fi)	1998-05-20	2004-04-15	Upm Kymmene Corp	Pakkauksenmuodostuslaite
PT1105122E (pt) *	1998-08-14	2005-08-31	Hoffmann La Roche	Composicoes farmaceuticas que contem inibidores de lipase
DE69916288T2 (de) *	1998-08-14	2005-03-24	F. Hoffmann-La Roche Ag	Lipasehemmer und chitosan enthaltende arzneimittel
WO2000013667A1 (en)	1998-09-08	2000-03-16	Smithkline Beecham Corporation	Lipstatin derivative-soluble fiber tablets
GB9900416D0 (en)	1999-01-08	1999-02-24	Alizyme Therapeutics Ltd	Inhibitors
WO2000043036A2 (en)	1999-01-22	2000-07-27	Hunza Di Maria Carmela Marazzita S.A.S.	Lipoprotein complexes and compositions containing them
AR025609A1 (es)	1999-09-13	2002-12-04	Hoffmann La Roche	Formulaciones lipidas solidas
AR025587A1 (es) *	1999-09-13	2002-12-04	Hoffmann La Roche	Formulaciones en dispersion que contienen inhibidores de lipasa
SI1307264T1 (en) *	2000-07-28	2005-02-28	F. Hoffmann-La Roche Ag	New pharmaceutical composition

2001
- 2001-07-19 SI SI200130249T patent/SI1307264T1/xx unknown
- 2001-07-19 AU AU8969901A patent/AU8969901A/xx active Pending
- 2001-07-19 JP JP2002515366A patent/JP4265911B2/ja not_active Expired - Lifetime
- 2001-07-19 RS YUP-50/03A patent/RS50397B/sr unknown
- 2001-07-19 IL IL15400801A patent/IL154008A0/xx unknown
- 2001-07-19 WO PCT/EP2001/008363 patent/WO2002009815A2/en active IP Right Grant
- 2001-07-19 CA CA002416901A patent/CA2416901C/en not_active Expired - Lifetime
- 2001-07-19 MX MXPA03000771A patent/MXPA03000771A/es active IP Right Grant
- 2001-07-19 HR HR20030029A patent/HRP20030029B1/xx not_active IP Right Cessation
- 2001-07-19 EP EP01969439A patent/EP1307264B1/en not_active Expired - Lifetime
- 2001-07-19 RU RU2003104801/15A patent/RU2241462C2/ru active
- 2001-07-19 PT PT01969439T patent/PT1307264E/pt unknown
- 2001-07-19 NZ NZ523684A patent/NZ523684A/en not_active IP Right Cessation
- 2001-07-19 ME MEP-2008-905A patent/ME00671B/me unknown
- 2001-07-19 HU HU0301281A patent/HU229292B1/hu unknown
- 2001-07-19 PL PL366105A patent/PL204443B1/pl unknown
- 2001-07-19 CN CNB018135196A patent/CN100423715C/zh not_active Expired - Lifetime
- 2001-07-19 ES ES01969439T patent/ES2230362T3/es not_active Expired - Lifetime
- 2001-07-19 BR BRPI0112799A patent/BR0112799B1/pt not_active IP Right Cessation
- 2001-07-19 AT AT01969439T patent/ATE279961T1/de active
- 2001-07-19 CZ CZ20030582A patent/CZ302087B6/cs not_active IP Right Cessation
- 2001-07-19 AU AU2001289699A patent/AU2001289699B2/en not_active Expired
- 2001-07-19 KR KR1020037001277A patent/KR100572785B1/ko not_active Expired - Fee Related
- 2001-07-19 DE DE60106623T patent/DE60106623T2/de not_active Expired - Lifetime
- 2001-07-24 PE PE2001000743A patent/PE20020336A1/es active IP Right Grant
- 2001-07-24 JO JO2001125A patent/JO2320B1/en active
- 2001-07-25 US US09/912,957 patent/US6756364B2/en not_active Expired - Lifetime
- 2001-07-26 PA PA20018523201A patent/PA8523201A1/es unknown
- 2001-07-26 AR ARP010103574A patent/AR033548A1/es not_active Application Discontinuation
- 2001-07-26 MY MYPI20013543 patent/MY127247A/en unknown
- 2001-07-27 UY UY26860A patent/UY26860A1/es not_active Application Discontinuation
- 2001-07-27 GT GT200100152A patent/GT200100152A/es unknown
- 2001-07-28 EG EG20010821A patent/EG24357A/xx active
- 2001-09-04 TW TWNEWPHARMA patent/TWI275395B/zh not_active IP Right Cessation
2003
- 2003-01-16 ZA ZA200300456A patent/ZA200300456B/en unknown
- 2003-01-16 IL IL154008A patent/IL154008A/en active IP Right Grant
- 2003-01-24 EC EC2003004450A patent/ECSP034450A/es unknown
- 2003-01-27 MA MA27015A patent/MA26937A1/fr unknown
- 2003-01-27 NO NO20030418A patent/NO330546B1/no not_active IP Right Cessation
- 2003-11-20 US US10/718,049 patent/US20040105838A1/en not_active Abandoned
2005
- 2005-02-18 US US11/062,086 patent/US20050136030A1/en not_active Abandoned
2006
- 2006-08-07 US US11/499,955 patent/US20060269510A1/en not_active Abandoned
2008
- 2008-09-09 JP JP2008230880A patent/JP2009073833A/ja active Pending
2010
- 2010-04-20 US US12/763,794 patent/US8071571B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP2009073833A (ja)	2009-04-09
HUP0301281A2 (hu)	2003-08-28
RU2241462C2 (ru)	2004-12-10
GT200100152A (es)	2002-05-16
IL154008A (en)	2011-12-29
UY26860A1 (es)	2002-01-31
PA8523201A1 (es)	2002-10-24
PT1307264E (pt)	2005-02-28
HRP20030029A2 (en)	2004-02-29
IL154008A0 (en)	2003-07-31
ATE279961T1 (de)	2004-11-15
MEP90508A (en)	2011-12-20
EP1307264B1 (en)	2004-10-20
KR100572785B1 (ko)	2006-04-19
MY127247A (en)	2006-11-30
AU8969901A (en)	2002-02-13
DE60106623T2 (de)	2006-02-02
AR033548A1 (es)	2003-12-26
ME00671B (me)	2011-12-20
HU229292B1 (en)	2013-10-28
KR20030029796A (ko)	2003-04-16
TWI275395B (en)	2007-03-11
NO20030418L (no)	2003-01-27
US20050136030A1 (en)	2005-06-23
PE20020336A1 (es)	2002-05-08
US20100203032A1 (en)	2010-08-12
EP1307264A2 (en)	2003-05-07
US20060269510A1 (en)	2006-11-30
US6756364B2 (en)	2004-06-29
CZ2003582A3 (cs)	2004-02-18
SI1307264T1 (en)	2005-02-28
CA2416901A1 (en)	2002-02-07
US8071571B2 (en)	2011-12-06
HRP20030029B1 (en)	2005-06-30
JP4265911B2 (ja)	2009-05-20
PL204443B1 (pl)	2010-01-29
CN1444495A (zh)	2003-09-24
ECSP034450A (es)	2003-03-10
WO2002009815A2 (en)	2002-02-07
NO330546B1 (no)	2011-05-16
AU2001289699B2 (en)	2006-06-01
CN100423715C (zh)	2008-10-08
ES2230362T3 (es)	2005-05-01
BR0112799B1 (pt)	2017-10-24
RS50397B (sr)	2009-12-31
DE60106623D1 (de)	2004-11-25
MXPA03000771A (es)	2003-06-04
NO20030418D0 (no)	2003-01-27
HUP0301281A3 (en)	2005-05-30
NZ523684A (en)	2005-04-29
US20040105838A1 (en)	2004-06-03
WO2002009815A3 (en)	2002-04-18
BR0112799A (pt)	2003-07-01
EG24357A (en)	2009-03-04
CZ302087B6 (cs)	2010-10-06
MA26937A1 (fr)	2004-12-20
YU5003A (sh)	2006-01-16
CA2416901C (en)	2007-07-03
PL366105A1 (en)	2005-01-24
JP2004505067A (ja)	2004-02-19
US20020035089A1 (en)	2002-03-21
JO2320B1 (en)	2005-09-12
HK1058636A1 (zh)	2004-05-28

Publication	Publication Date	Title
US6756364B2 (en)	2004-06-29	Method of reducing gastrointestinal side effects associated with orlistat treatment
AU2001289696B2 (en)	2006-07-06	New use of lipase inhibitors
AU2001289699A1 (en)	2002-05-09	New pharmaceutical composition
AU2001289696A1 (en)	2002-05-09	New use of lipase inhibitors
HK1058636B (en)	2009-01-16	New pharmaceutical composition